Cover Image
市場調查報告書

絲蟲病(淋巴系絲蟲症):開發平台分析

Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 302485
出版日期 內容資訊 英文 26 Pages
訂單完成後即時交付
價格
Back to Top
絲蟲病(淋巴系絲蟲症):開發平台分析 Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017
出版日期: 2017年07月18日 內容資訊: 英文 26 Pages
簡介

絲蟲病(別名:淋巴系絲蟲症)是絲蟲寄生蟲透過蚊子傳播到人體而發病的傳染病。一般是在幼兒期感染,對淋巴系統造成隱性傷害。被分類為family Filariodidea的蛔蟲感染是造成該疾病的主要致病原因。主要症狀有朣脹、發冷顫抖、發汗、頭痛、嘔吐等。主要治療法為抗生素。

本報告提供全球各國治療絲蟲病(淋巴系絲蟲症)所用的開發中產品之開發情形相關分析,提供您開發中產品的開發·上市最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等調查。

目錄

簡介

  • 分析範圍

絲蟲病概要

治療藥的開發

  • 絲蟲病開發中產品:概要
  • 絲蟲病開發中產品:比較分析

各企業正在開發的絲蟲病治療藥

大學/研究機關研究中的絲蟲病治療藥

開發中產品的概要

  • 初期階段的產品

絲蟲病治療藥:開發中的產品一覽(各企業)

絲蟲病治療藥:研究中的產品一覽(大學/研究機關別)

絲蟲病開發治療藥的企業

  • Johnson & Johnson
  • Eisai
  • Anacor Pharmaceuticals, Inc.

絲蟲病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各分子類型

藥物簡介

  • 絲蟲症疫苗
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • flubendazole
  • IIC-942A001
  • IIC-950A001
  • 淋巴系絲蟲症小分子
  • S-0112091
  • S-0112094
  • 絲蟲病小分子
  • 淋巴系絲蟲症小分子
  • 淋巴系絲蟲症·線狀蟲病小分子
  • 線蟲病小分子

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9553IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017, provides an overview of the Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline landscape.

Elephantiasis commonly known as Lymphatic filariasis occurs when filarial parasites are transmitted to humans through mosquitoes. Infection is usually acquired in childhood causing hidden damage to the lymphatic system. Lymphatic filariasis is caused by infection with parasites classified as nematodes (roundworms) of the family Filariodidea. Symptoms include swelling, shaking chills, sweating, headaches, and vomiting. Treatment includes antibiotics.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Elephantiasis (Lymphatic Filariasis) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Elephantiasis (Lymphatic Filariasis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Elephantiasis (Lymphatic Filariasis) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Elephantiasis (Lymphatic Filariasis) (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Elephantiasis (Lymphatic Filariasis) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Elephantiasis (Lymphatic Filariasis) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Elephantiasis (Lymphatic Filariasis) - Overview
    • Elephantiasis (Lymphatic Filariasis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Elephantiasis (Lymphatic Filariasis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Elephantiasis (Lymphatic Filariasis) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Eisai Co Ltd
    • Johnson & Johnson
  • Elephantiasis (Lymphatic Filariasis) - Drug Profiles
    • AbbV-4083 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EDE-1206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • filariasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flubendazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lymphatic filariasis (multivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Lymphatic Filariasis and Onchocerciasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by AbbVie Inc, H2 2017
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Eisai Co Ltd, H2 2017
  • Elephantiasis (Lymphatic Filariasis) - Pipeline by Johnson & Johnson, H2 2017
  • Elephantiasis (Lymphatic Filariasis) - Dormant Projects, H2 2017

List of Figures

  • Number of Products under Development for Elephantiasis (Lymphatic Filariasis), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top